Archived AES Symposia 2005
Annual Course - Evidence Used to Diagnose and Treat Patients
Program Length: 4 hrs 57 min
This years Annual Course will provide an overview of evidence-based medicine in the care of epilepsy patients. Basic clinical issues will be addressed including accuracy of diagnosis and when to start and stop AEDs. The role of EEG, video EEG, and other laboratory studies in diagnosis and treatment will be discussed. Controversial topics such as the treatment of status epilepticus based on EEG findings and the value of guidelines for selecting AEDs will be debated. Therapeutic challenges such as management of women and the elderly will also be discussed with a focus on the gaps in our knowledge as well as recent data. Finally, data on injuries, the progression of cognitive and structural changes in epilepsy and sudden death will also be covered, including recommendations about counseling patients.
Physicians, neurologists, epileptologists, neuro-electrophysiologists, nurses, pharmacists residents, students and fellows.
At the conclusion of this activity, participants should be able to:
- Apply the principles of evidence-based medicine for your patients presenting with epilepsy
- Develop a diagnostic strategy to correctly diagnose epilepsy in your patient population
- Monitor epilepsy patients for toxicity with the most effective treatment approaches
- Demonstrate effective treatment for the care of your patients with status epilepticus
- Determine appropriate utilization of EEG when required for the diagnosis of your patients
- Determine the appropriate treatment regimes for your patients, including women, children and the elderly
- Choose the best medication for newly diagnosed patients and those with refractory treatment and treat for an optimal length of time
- Counsel patients, families and caretakers regarding how to reduce injury and sudden death for the person with epilepsy in their care.
Concurrent Afternoon Sessions
I. Evidence Used to Diagnose and Treat Patients
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Selim R. Benbadis, MD Consultant: Abbott, Cyberonics, Inc., Eisai, GlaxoSmithKline, Novartis, Ortho McNeil, Pfizer, Inc., Sleepmed/DigiTrace, and UCB Pharma
Elinor Ben-Menachem, MD, PhD Consultant/Honorarium: Cyberonics, Neurosearch, OrthoMcNeil, Pfizer, Inc., Schwarz Bioscience, and UCB Pharma Grants: BIAL, Cyberonics, Inc., Neurosearch, Schwarz Bioscience, and UCB Pharma
Warren T. Blume, MD Dr. Blume has no real or apparent conflicts of interest to report
Richard P. Brenner, MD Dr. Brenner has no real or apparent conflicts of interest to report
Peter Camfield, MD, FRCP(C) Dr. Camfield has no real or apparent conflicts of interest to report
David W. Chadwick, MD Consultant: Pfizer, Inc. Research support: Novartis, Sanofi, and Serono
Orrin Devinsky, MD (Liaison Reviewer) Honorarium for non-CME services: UCB Pharma
Dennis J. Dlugos, MD Consultant: Eisai, Johnson & Johnson Research and Development, Ortho-McNeil, and UCB Pharma Honorarium: Eisai, GlaxoSmithKline, and Ortho-McNeil
Nathan B. Fountain, MD Grants: Eisai, Johnson & Johnson, Medtronic, Neuropace, Pfizer, Inc., Schwarz Biosciences, and UCB Pharma
John M. Freeman, MD Dr. Freeman has no real or apparent conflicts of interest to report
Jacqueline A. French, MD Grants/Honorarium, and/or Consultant: Eisai, GlaxoSmithKline, Medpointe, Novartis, Ortho-McNeil, Pfizer, Inc., and UCB Pharma
Lawrence J. Hirsch, MD Consultant: Eisai Honorarium: GlaxoSmithKline Grants: GlaxoSmithKline, Novartis, and UCB Pharma Negotiating research support from Abbott, Pfizer, Inc., and Eisai
Richard A. Hrachovy, MD Dr. Hrachovy has no real or apparent conflicts of interest to report
Vicente Iraqui, MD (Liaison Reviewer) Consultant: UCB Pharma Honorarium for non-CME: Abbott and Novartis
Kenneth G. Jordan, MD, FACP President, CEO and principal shareholder of Jordan NeuroScience, Inc, manufacturer of the BraiNet EEG Set-up Template
Fred Lado, MD, PhD (Liaison Reviewer) Dr. Lado has no real or apparent conflicts of interest to report
Ilo E. Leppik, MD Grants: NIH Honorarium/Consultant: (fees given directly to the University of Minnesota) Chair: Medtronic SANTE trial Data and Safety monitoring committee He is now or has been a consultant or speaker for almost all of the pharmaceutical companies.
Dan Lowenstein, MD Advisory Board: Epilepsy Therapy Development Project and Neurologix, Inc. Consultant: Intranasal Therapeutics, Inc.
Dan Mayer, MD Dr. Mayer has no real or apparent conflicts of interest to report
John W. Miller, MD, PhD (Liaison Reviewer) Dr. Miller has no real or apparent conflicts of interest to report
Siddhartha S. Nadkarni, MD Dr. Nadkarni has no real or apparent conflicts of interest to report
Douglas R. Nordli, Jr., MD Consultant: Johnson & Johnson, Novartis, and UCB Pharma
Page B. Pennell, MD (Liaison Reviewer) Consultant/Honorarium: GlaxoSmithKline, Lineberry Research Associates, and UCB Pharma Grants: GlaxoSmithKline, Pfizer, Inc., and NIH
Rodney A. Radtke, MD Advisory Boards: GlaxoSmithKline, Novartis, and UCB Pharma Speakers bureau: Eisai, GlaxoSmithKline, Novartis, OrthoMcNeil, and UCB Pharma Grants: UCB Pharma
Donald L. Schomer, MD Consultant/Honorarium: Abbott Laboratories, Eisai, GlaxoSmithKline, and UCB Pharma Medical director for EEG services, consultant, founding member, <1% ownership: SleepMed/Digitrace
Elson L. So, MD Dr. So has no real or apparent conflicts of interest to report
Michael R. Sperling, MD Speakers Bureau: Cyberonics, Inc, Eisai, GlaxoSmithKline, Novartis, Ortho-McNeill, Pfizer, Inc., and UCB Pharma Grants: GlaxoSmithKline, Ortho-McNeill, and Schwarz Bioscience
Cees van Donselaar, MD Dr. van Donselaar has no real or apparent conflicts of interest to report
Eileen PG. Vining, MD (Liaison Reviewer) Dr. Vining has no real or apparent conflicts of interest to report
Elaine C. Wirrell, MD Dr. Wirrell has no real or apparent conflicts of interest to report
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.